ClinicalTrials.gg
CompletedNCT04649385Updated Jun 26, 2026

BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors

A Phase 1 interventional study of BGB-15025 and Tislelizumab in Advanced Solid Tumor, sponsored by BeiGene. Completed at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2025, 1 year 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
157
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Phase 1a (dose escalation): Participants with or cytologically confirmed advanced, , and unresectable solid tumors who have previously received standard systemic therapy or for whom treatment is not available, not tolerated or refused, and who have not received prior therapy targeting HPK1
  2. Phase 1b (dose expansion): Participant with histologically or cytologically confirmed advanced, and metastatic including non-small cell lung cancer, and gastric/Gastroesophageal junction cancer that have no prior systemic treatment for advanced disease and esophageal squamous cancer who have progressed following systemic anticancer therapies
  3. At least 1 as defined per 1.1.
  4. (ECOG) Performance Status ≤ 1
  5. Adequate organ function as indicated by the following laboratory values up to first dose of study treatment: ≥ 90 g/L, ≥ 1.5 x 10\^9/L , Serum total ≤ 1.5 x (\< 3 x ULN for participants with Gilbert syndrome ), and ALT≤ 2.5 x ULN

Key Exclusion Criteria:

  1. Active or uncontrolled and untreated .
  2. Active diseases or history of autoimmune diseases that may relapse
  3. Any active ≤ 2 years before the first dose of study treatment except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
  4. Any condition that required systemic treatment with either (> 10 mg daily of prednisone or equivalent) or other medication ≤ 14 days before the first dose of study treatment
  5. History of interstitial lung disease, noninfectious pneumonitis, or uncontrolled lung diseases including but not limited to pulmonary fibrosis, acute lung diseases, etc.
  6. For Cohort A: Known actionable mutations (including but not limited to epidermal growth factor receptor (EGFR) gene, anaplastic lymphoma kinase (ALK) fusion oncogene, BRAF V600E, RET, MET, and ROS1, for which a targeted therapy has been approved by the local health authority and available.
  7. For Cohort B: Diagnosed with G/GEJ adenocarcinoma with positive status

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
157 participants (actual)

Study arms

  • Experimental
    Phase 1a: Dose Escalation

    Part A: Participants will receive once daily of BGB-15025 monotherapy in sequential cohorts of approximately 7 increasing doses Part B: Participants will receive once daily of BGB-15025 in sequential cohorts plus 200mg tislelizumab on day 1 of each 21-day cycle (combination therapy )

    Drug: BGB-15025 · Drug: Tislelizumab

  • Experimental
    Phase 1b: Dose Expansion

    Phase 1b dose expansion will begin based upon the recommended doses for expansion (RDFE) for BGB-15025 alone or in combination with tislelizumab, and with or without chemotherapy as determined from Phase 1a

    Drug: BGB-15025 · Drug: Tislelizumab · Drug: Carboplatin · Drug: Cisplatin · Drug: Pemetrexed · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Paclitaxel · Drug: nab-paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Phase 1a: Number of participants with dose limiting toxicities (DLTs)

    Participants will be considered evaluable for DLTs if they 1) received ≥ 80% of each scheduled study treatment administration during the DLT assessment window and/or 2) experienced a DLT.

    Time frame: Up to 3 Years

  2. Phase 1a: Number of Participants Experiencing Adverse Events (AEs)

    Time frame: Up to 4 Years

  3. Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)

    Time frame: Up to 4 years

  4. The maximum tolerated dose (MTD) of BGB-15025

    The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%

    Time frame: Up to 3 Years

  5. Recommended Doses for Expansion (RDFE) of BGB-15025 monotherapy

    The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%

    Time frame: Up to 3 years

  6. RDFE of BGB-15025 in combination with tislelizumab

    The highest dose evaluated for which the estimated toxicity rate is closest to the target toxicity rate of 30%

    Time frame: Up to 3 years

  7. Phase 1b: Overall Response Rate (ORR) as assessed by the investigator

    Time frame: Up to 2 years

Secondary outcomes

  1. Phase 1a: Overall Response Rate (ORR) as assessed by the investigator

    Time frame: Up to 3 years

  2. Duration Of Response (DOR) as assessed by the investigator

    Time frame: Up to 3 years

  3. Disease Control Rate (DCR) as assessed by the investigator

    Time frame: Up to 3 years

  4. Phase 1a: Maximum observed plasma concentration (Cmax) of BGB-15025

    Time frame: Predose up to 8 hours postdose

  5. Phase 1a: Minimum observed plasma concentration (Cmin) of BGB-15025

    Time frame: Predose up to 8 hours postdose

  6. Phase 1a: Time to maximum plasma concentration (Tmax) of BGB-15025

    Time frame: Predose up to 8 hours postdose

  7. Phase 1a: Half-life of (t1/2) of BGB-15025

    Time frame: Predose up to 8 hours postdose

  8. Phase 1a: Area under the concentration-time curve (AUC) of BGB-15025

    Time frame: Predose up to 8 hours postdose

  9. Phase 1a: Apparent clearance (CL/F) of BGB-15025

    Time frame: Predose up to 8 hours postdose

  10. Phase 1a: Apparent volume of distribution (Vz/F) of BGB-15025

    Time frame: Predose up to 8 hours postdose

  11. Phase 1a: Accumulation Ratio for Cmax of BGB-15025

    Time frame: Predose up to 8 hours postdose

  12. Phase 1a: Accumulation Ratio for AUC of BGB-15025

    Time frame: Predose up to 8 hours postdose

  13. Phase 1a: Metabolite to parent ratio for BGB-15025 and its metabolite

    Time frame: Predose up to 8 hours postdose

  14. Phase 1b: Number of Participants Experiencing Adverse Events (AEs)

    Time frame: Up to 3 years

  15. Phase 1b: Number of Participants Experiencing Serious Adverse Events (SAEs)

    Time frame: Up to 3 years

  16. Phase 1b: Plasma Concentrations of BGB-15025

    Time frame: Predose up to 8 hours postdose

  17. Phase 1b: Plasma Concentrations of the metabolite

    Time frame: Predose up to 8 hours postdose

  18. Phase 1b: Number of participants with dose limiting toxicities (DLTs)

    Participants will be considered evaluable for DLTs if they 1) received ≥ 80% of each scheduled study treatment administration during the DLT assessment window and/or 2) experienced a DLT.

    Time frame: Up to 1 year

07

Study locations

20 sites
  • Icahn School of Medicine At Mount Sinai
    New York, New York 10029-6504, United States
  • The University of Texas Md Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • Ut Health San Antonio Mays Cancer Center
    San Antonio, Texas 78229-4427, United States
  • Prince of Wales Hospital
    Randwick, New South Wales NSW 2031, Australia
  • Ashford Cancer Centre Research Northeast
    Windsor Gardens, South Australia SA 5087, Australia
  • Peter Maccallum Cancer Centre
    Melbourne, Victoria VIC 3000, Australia
  • Linear Clinical Research
    Nedlands, Western Australia WA 6009, Australia
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 150000, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
  • Shanghai Pulmonary Hospital
    Shanghai, Shanghai Municipality 200433, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin Municipality 300060, China
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310016, China
  • Auckland City Hospital
    Auckland, 1023, New Zealand
  • Seoul National University Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, South Korea
  • Samsung Medical Center
    GangnamGu, Seoul Teugbyeolsi 06351, South Korea
  • The Catholic University of Korea, Seoul St Marys Hospital
    SeochoGu, Seoul Teugbyeolsi 06591, South Korea
  • Severance Hospital Yonsei University Health System
    SeodaemunGu, Seoul Teugbyeolsi 03722, South Korea
  • Asan Medical Center
    SongpaGu, Seoul Teugbyeolsi 05505, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beonemedicines.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Oct 2025, 55 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2020
First posted
Dec 2, 2020
StartActual
Mar 4, 2021
Primary completionActual
Oct 17, 2025
CompletionActual
May 15, 2026
Last update
Jun 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04649385
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Dec 2, 2020
Start date
Mar 4, 2021
Primary completion
Oct 17, 2025
Completion
May 15, 2026
Last update
Jun 26, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion